Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
- PMID: 17109672
- DOI: 10.1111/j.1742-1241.2006.01196.x
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
Abstract
The therapeutic options for treating type 2 diabetes have been widened by the introduction of exenatide as the first incretin mimetic. Incretins are gut hormones that contribute to the stimulation of insulin secretion after a carbohydrate rich meal. The incretin hormone glucagon-like peptide-1 (GLP-1) not only stimulates insulin secretion under hyperglycaemic conditions, but also suppresses glucagon secretion, slows gastric emptying, induces satiety and improves beta cell function in type 2 diabetes. These beneficial effects have awakened the interest to use GLP-1 for the treatment of type 2 diabetes. Because of its short biological half-life, GLP-1 itself is not practical for type 2 diabetes therapy. Exenatide is a peptide found in the lizard Heloderma suspectum and has a high similarity to GLP-1. Exenatide belongs to the novel class of incretin mimetics because of its incretin-like action. It has a much longer biological half life than GLP-1 and is a GLP-1 receptor agonist that can be used for therapeutic purposes by twice daily injection. Clinical studies and clinical experience with exenatide have shown a significant reduction in HbA1c, fasting- and postprandial glucose and a marked reduction in body weight in type 2 diabetic patients. Animal studies reveal an improvement of beta cell function and an increase in beta cell mass after exenatide treatment. This review gives an overview on exenatide, its pharmacological profile and its role and potential in the therapeutic setting of type 2 diabetes. Furthermore, future developments concerning exenatide application are highlighted.
Comment in
-
Exenatide and pramlintide: new therapies for diabetes.Int J Clin Pract. 2006 Dec;60(12):1522-3. doi: 10.1111/j.1742-1241.2006.01219.x. Int J Clin Pract. 2006. PMID: 17109659 No abstract available.
Similar articles
-
Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.Diabetes Educ. 2008 May-Jun;34 Suppl 3:66S-72S. doi: 10.1177/0145721708319238. Diabetes Educ. 2008. PMID: 18525067
-
Therapies for the treatment of type 2 diabetes mellitus based on incretin action.Minerva Endocrinol. 2006 Jun;31(2):133-47. Minerva Endocrinol. 2006. PMID: 16682937 Review.
-
Incretins and other peptides in the treatment of diabetes.Diabet Med. 2007 Mar;24(3):223-32. doi: 10.1111/j.1464-5491.2006.02071.x. Diabet Med. 2007. PMID: 17263764 Review.
-
Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.Diabet Med. 2009 Sep;26(9):935-8. doi: 10.1111/j.1464-5491.2009.02789.x. Diabet Med. 2009. PMID: 19719716
-
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S26-34. doi: 10.1016/S0168-8227(09)70006-3. Diabetes Res Clin Pract. 2009. PMID: 20115929
Cited by
-
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.Rev Diabet Stud. 2006 Winter;3(4):208-16. doi: 10.1900/RDS.2006.3.208. Epub 2007 Feb 10. Rev Diabet Stud. 2006. PMID: 17487346 Free PMC article.
-
Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.Mol Endocrinol. 2011 Oct;25(10):1804-18. doi: 10.1210/me.2011-1160. Epub 2011 Aug 25. Mol Endocrinol. 2011. PMID: 21868452 Free PMC article.
-
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.Clin Med Insights Endocrinol Diabetes. 2011;4:1-12. doi: 10.4137/CMED.S5114. Epub 2011 Jan 12. Clin Med Insights Endocrinol Diabetes. 2011. PMID: 22879789 Free PMC article.
-
Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).Drugs. 2007;67(6):935-54. doi: 10.2165/00003495-200767060-00008. Drugs. 2007. PMID: 17428109 Review.
-
Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.Curr Ther Res Clin Exp. 2010 Aug;71(4):211-38. doi: 10.1016/j.curtheres.2010.08.003. Curr Ther Res Clin Exp. 2010. PMID: 24688145 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical